These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28243182)

  • 1. Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.
    Sørensen PS; Comi G; Vollmer TL; Montalban X; Kappos L; Dadon Y; Gorfine T; Margalit M; Sasson N; Rubinchick S; Knappertz V
    Int J MS Care; 2017; 19(1):16-24. PubMed ID: 28243182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
    Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L
    J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Giovannoni G; Knappertz V; Steinerman JR; Tansy AP; Li T; Krieger S; Uccelli A; Uitdehaag BMJ; Montalban X; Hartung HP; Pia Sormani M; Cree BAC; Lublin F; Barkhof F
    Neurology; 2020 Aug; 95(8):e1027-e1040. PubMed ID: 32651286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
    Cutter GR; Knappertz V; Sasson N; Ladkani D
    BMC Neurol; 2016 Sep; 16():176. PubMed ID: 27639853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
    Filippi M; Rocca MA; Pagani E; De Stefano N; Jeffery D; Kappos L; Montalban X; Boyko AN; Comi G;
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):851-8. PubMed ID: 24029546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laquinimod therapy in multiple sclerosis: a comprehensive review.
    Kolb-Sobieraj C; Gupta S; Weinstock-Guttman B
    Neurol Ther; 2014 Jun; 3(1):29-39. PubMed ID: 26000222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
    Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
    Stasiolek M; Linker RA; Hayardeny L; Bar Ilan O; Gold R
    Immun Inflamm Dis; 2015 Jun; 3(2):45-55. PubMed ID: 26029365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
    N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
    Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
    Elgart A; Zur AA; Mimrod D; Dror V; Bar-Ilan O; Korver T; Spiegelstein O
    Eur J Clin Pharmacol; 2019 Jan; 75(1):41-49. PubMed ID: 30191262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings.
    Kappos L; Cohen J; Collins W; de Vera A; Zhang-Auberson L; Ritter S; von Rosenstiel P; Francis G
    Mult Scler Relat Disord; 2014 Jul; 3(4):494-504. PubMed ID: 25877062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
    MacGregor EA; Pawsey SP; Campbell JC; Hu X
    Gend Med; 2010 Apr; 7(2):88-108. PubMed ID: 20435272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics for induction and maintenance of remission in Crohn's disease.
    Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.